XML 20 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 5,499 $ 8,077
Short-term investments 1,751 3
Accounts receivable, less allowances of $197 and $193 7,931 8,221
Inventories 5,133 5,088
Contract assets, net 1,422 1,443
Other current assets 1,904 1,757
Total current assets 23,640 24,589
Property, plant and equipment, net 9,324 9,448
Acquisition-related intangible assets, net 16,048 16,670
Other assets 4,241 3,999
Goodwill 43,843 44,020
Total assets 97,095 98,726
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 4,451 3,609
Accounts payable 2,555 2,872
Accrued payroll and employee benefits 1,314 1,596
Contract liabilities 2,632 2,689
Other accrued expenses 2,985 3,246
Total current liabilities 13,937 14,012
Deferred income taxes 1,811 1,922
Other long-term liabilities 4,567 4,642
Long-term obligations 31,157 31,308
Redeemable noncontrolling interest 119 118
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued 0 0
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,822,699 and 442,188,634 shares issued 443 442
Capital in excess of par value 17,482 17,286
Retained earnings 48,542 47,364
Treasury stock at cost, 61,106,376 and 55,541,290 shares (18,186) (15,133)
Accumulated other comprehensive income/(loss) (2,764) (3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity 45,516 46,735
Noncontrolling interests (12) (11)
Total equity 45,504 46,724
Total liabilities, redeemable noncontrolling interest and equity $ 97,095 $ 98,726